Moderna Stock Is Upgraded on Growth Opportunities Not Related to Covid


was rising Monday after an analyst at Jefferies upgraded the inventory citing confidence within the vaccine maker’s progress alternatives that aren’t associated to the Covid-19 vaccine.

Jefferies analyst Michael Yee upgraded shares of Moderna (ticker: MRNA) to Buy from Hold and elevated his 12-month worth goal on the inventory to $275 from $170. For Moderna, Yee mentioned he sees a “significant new pipeline story and catalysts ahead.”